Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis
Clicks: 329
ID: 115475
2019
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
85.2
/100
322 views
261 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Vedolizumab was associated with significantly higher deep remission rates than placebo at Week 52, regardless of deep remission definition [NCT00783718].
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (19 words).
Try re-searching for a better abstract.
| Reference Key |
wj2019journaldeep
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Sandborn WJ;Colombel JF;Panaccione R;Dulai PS;Rosario M;Cao C;Barocas M;Lasch K;; |
| Journal | journal of crohn's & colitis |
| Year | 2019 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
adult
female
male
adolescent
aged
middle aged
young adult
Randomized Controlled Trial
Antibodies
Monoclonal
severity of illness index
Humanized / therapeutic use*
Colitis
Ulcerative / drug therapy*
Gastrointestinal Agents / therapeutic use*
remission induction / methods
ulcerative / pathology
pmid:30285104
pmc6357899
doi:10.1093/ecco-jcc/jjy149
william j sandborn
jean-frédéric colombel
karen lasch
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.